[go: up one dir, main page]

CN103601779B - The synthetic method of 7-denitrification-2 '-deoxidation-7-halogen 9 substituted guanine nucleosides - Google Patents

The synthetic method of 7-denitrification-2 '-deoxidation-7-halogen 9 substituted guanine nucleosides Download PDF

Info

Publication number
CN103601779B
CN103601779B CN201310489397.0A CN201310489397A CN103601779B CN 103601779 B CN103601779 B CN 103601779B CN 201310489397 A CN201310489397 A CN 201310489397A CN 103601779 B CN103601779 B CN 103601779B
Authority
CN
China
Prior art keywords
compound
deaza
add
solution
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310489397.0A
Other languages
Chinese (zh)
Other versions
CN103601779A (en
Inventor
沈玉梅
邵志峰
龚兵
刘亚智
赵小东
江敏
李小卫
汤道年
伍新燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiao Tong University
Original Assignee
Shanghai Jiao Tong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiao Tong University filed Critical Shanghai Jiao Tong University
Priority to CN201310489397.0A priority Critical patent/CN103601779B/en
Publication of CN103601779A publication Critical patent/CN103601779A/en
Application granted granted Critical
Publication of CN103601779B publication Critical patent/CN103601779B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Saccharide Compounds (AREA)

Abstract

本发明公开了一种7-去氮-2’-脱氧-7-卤素取代鸟嘌呤核苷的合成方法;所述方法包括将下式(V)化合物在碱性条件下去甲基得到下式(I)化合物,即所述7-去氮-2’-脱氧-7-卤素取代鸟嘌呤核苷;(I),(V),其中R2为I、Br或Cl。本发明合成的7-去氮-7-碘-2’-脱氧鸟嘌呤核苷是在DNA测序、标记、延伸等生物学领域广泛使用的基本原料,目前其销售价格很高,且合成方法复杂;而本发明提供的合成方法所需原料简单易得,合成过程均为常规化学反应,可用于大规模推广使用。

The invention discloses a synthesis method of 7-deaza-2'-deoxy-7-halogen substituted guanosine; the method comprises demethylating the compound of the following formula (V) under alkaline conditions to obtain the following formula ( I) a compound, that is, the 7-deaza-2'-deoxy-7-halogen substituted guanosine; (I), (V), wherein R 2 is I, Br or Cl. The 7-deaza-7-iodo-2'-deoxyguanosine synthesized by the present invention is a basic raw material widely used in biological fields such as DNA sequencing, labeling, and extension. Currently, its selling price is very high, and its synthesis method is complicated ; And the raw materials needed for the synthetic method provided by the invention are simple and easy to get, and the synthetic process is a conventional chemical reaction, which can be used for large-scale popularization.

Description

7-去氮-2’-脱氧-7-卤素取代鸟嘌呤核苷的合成方法Synthetic method of 7-deaza-2'-deoxy-7-halogen substituted guanosine

技术领域technical field

本发明涉及化学合成和生物化学领域,具体涉及一种7-去氮-2’-脱氧-7-卤素取代鸟嘌呤核苷(简称鸟苷dG-X)的合成方法。The invention relates to the fields of chemical synthesis and biochemistry, in particular to a synthesis method of 7-deaza-2'-deoxy-7-halogen substituted guanosine (guanosine dG-X for short).

背景技术Background technique

DNA测序技术是现代生命科学和医学研究的重要手段之一。DNA测序从1977年的Sanger测序技术(一代测序)开始,在三十几年的时间里,飞速发展。测序的通量大幅提高而成本急剧下降,有人甚至认为其发展的速度打破了半导体工业界已有的摩尔定律预算的速度。二代高通量平行测序技术的出现是测序技术飞速发展的集中体现。采用第一代测序技术,人类基因组计划(HGP)耗资30亿美元完成人整个基因组(30亿个碱基)的序列测定。而目前的二代测序的最新技术仅需5000美元左右就能完成人整个基因组测序。DNA sequencing technology is one of the important means of modern life science and medical research. DNA sequencing started with Sanger sequencing technology (generation sequencing) in 1977, and has developed rapidly in the past thirty years. The throughput of sequencing has been greatly increased and the cost has dropped sharply. Some people even think that the speed of its development has broken the existing Moore's Law budget in the semiconductor industry. The emergence of second-generation high-throughput parallel sequencing technology is a concentrated expression of the rapid development of sequencing technology. Using first-generation sequencing technology, the Human Genome Project (HGP) spent $3 billion to sequence the entire human genome (3 billion bases). However, the current state-of-the-art technology of next-generation sequencing can complete the sequencing of the entire human genome for only about US$5,000.

虽然如此,二代测序的成本和技术方面依然存在不足,不能满足基础科学和临床医学对测序的要求。单分子测序技术(三代测序技术)应运而生。三代测序技术的核心是直接对单个DNA分子进行测序,不做任何的DNA扩增反应,从而减少成本,提高通量。单分子测序技术虽然已有商业化产品,但是都还存在技术上的难点,未能大规模应用。Even so, the cost and technical aspects of next-generation sequencing are still insufficient, which cannot meet the requirements of basic science and clinical medicine for sequencing. Single-molecule sequencing technology (third-generation sequencing technology) came into being. The core of the third-generation sequencing technology is to directly sequence a single DNA molecule without any DNA amplification reaction, thereby reducing costs and increasing throughput. Although single-molecule sequencing technologies have been commercialized, they still have technical difficulties and cannot be applied on a large scale.

目前市场上的高通量测序平台被少数几家国外产品所垄断,尤其令人忧虑的是,国外公司凭借对测序试剂的控制,几乎完全控制了国内的测序市场,即便是测序硬件上我们能有所突破,在测序试剂等配套产品上我们还将受制于人。因此,自主研发可适用于二代测序甚至是三代测序平台的测序试剂,将对改变目前的市场格局、建立我国自主的测序平台具有战略性的意义。为此,国家863、973和“十二五”生物技术发展规划都将研发新一代测序技术及配套产品的研发列为重点发展的对象。At present, the high-throughput sequencing platform on the market is monopolized by a few foreign products. What is particularly worrying is that foreign companies have almost completely controlled the domestic sequencing market by virtue of their control over sequencing reagents. If we make breakthroughs, we will still be constrained by others in terms of sequencing reagents and other supporting products. Therefore, independent research and development of sequencing reagents that can be applied to second-generation sequencing or even third-generation sequencing platforms will have strategic significance for changing the current market structure and establishing my country's own independent sequencing platform. For this reason, the national 863, 973 and "Twelfth Five-Year Plan" biotechnology development plans all list the research and development of next-generation sequencing technology and supporting products as key development objects.

用于测序的可逆终端一股都选取U,C,A,G四个碱基的核苷酸.我们在实际工作中发现用于合成四个不同碱基核苷酸的起始原料,即四个不同碱基(U,C,A,G)的含取代基核苷价格昂贵,尤其是7-去氮-2’-脱氧-7-卤素取代鸟嘌呤核苷(简称鸟苷dG-X)不但非常昂贵而且合成方法很复杂,致使很多研究工作者尽量避免使用鸟苷(J.Org.Chem.2011,76,3457-3462),这样使原本完美的研究工作变得有些遗憾。如果是在必须四个碱基的情况下,不得不花重金购买。本发明用一种简单方便的方法合成得到了该类化合物且合成方法简单,反应条件温和,反应过程可控,适合大规模生产。并且用我们自己合成的鸟苷成功地合成了7-去氮-7-丙炔胺-2’-脱氧鸟嘌呤核苷酸dGTP(AP3)。The reversible terminal used for sequencing generally selects nucleotides with four bases U, C, A, and G. We have found in practical work that the starting materials for the synthesis of four different base nucleotides, that is, four Substituent nucleosides with different bases (U, C, A, G) are expensive, especially 7-deaza-2'-deoxy-7-halogen substituted guanosine (guanosine dG-X for short) Not only is it very expensive, but also the synthesis method is very complicated, so many researchers try to avoid using guanosine (J.Org.Chem.2011, 76, 3457-3462), which makes the original perfect research work a bit regrettable. If it is in the case of four bases, you have to spend a lot of money to buy them. The present invention synthesizes the compound by a simple and convenient method, and the synthesis method is simple, the reaction condition is mild, the reaction process is controllable, and it is suitable for large-scale production. And we successfully synthesized 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide dGTP (AP 3 ) with our own guanosine.

发明内容Contents of the invention

本发明的目的在于提供一种7-去氮-2’-脱氧-7-卤素取代鸟嘌呤核苷(简称鸟苷dG-X)的合成方法;该方法合成原料简单、便宜,反应条件温和,操作简单,可适合大规模生产。The object of the present invention is to provide a kind of synthetic method of 7-deaza-2'-deoxy-7-halogen substituted guanosine (guanosine dG-X for short); The synthetic raw material of this method is simple, cheap, and reaction condition is gentle, The operation is simple and suitable for mass production.

本发明的目的是通过以下技术方案来实现的:The purpose of the present invention is achieved through the following technical solutions:

本发明涉及一种7-去氮-2’-脱氧-7-卤素取代鸟嘌呤核苷的合成方法,所述方法包括将下式(V)化合物在碱性条件下去甲基得到下式(I)化合物,即所述7-去氮-2’-脱氧-7-卤素取代鸟嘌呤核苷;The present invention relates to a kind of synthetic method of 7-deaza-2'-deoxy-7-halogen substituted guanosine, said method comprises demethylating the compound of following formula (V) to obtain following formula (I ) compound, that is, the 7-deaza-2'-deoxy-7-halogen substituted guanosine;

(I),(I),

(V),其中R2为I、Br或Cl。(V), wherein R 2 is I, Br or Cl.

优选的,所述式(V)化合物通过在碱性条件下将式(IV)化合物去保护基制备而得:Preferably, the compound of formula (V) is prepared by deprotecting the compound of formula (IV) under basic conditions:

(IV),其中,R为保护羟基或氨基的保护基。 (IV), wherein, R is a protecting group for protecting a hydroxyl group or an amino group.

优选的,所述保护基为新戊酰基或异丁酰基。Preferably, the protecting group is pivaloyl or isobutyryl.

优选的,所述式(IV)化合物通过在式(III)化合物的嘌呤碱基的7位接上卤素制备而得:Preferably, the compound of formula (IV) is prepared by attaching a halogen to the 7-position of the purine base of the compound of formula (III):

(III)。可采用用NIS或其它碘化试剂在嘌呤碱基的7位接上碘;也可采用NBS或NCS等试剂在嘌呤碱基的7位接上溴或者氯。(III). Iodine can be connected to the 7-position of the purine base with NIS or other iodination reagents; bromine or chlorine can also be connected to the 7-position of the purine base with NBS or NCS and other reagents.

优选的,所述式(III)化合物通过在碱性条件下用保护基保护式(II)化合物的两个羟基和一个氨基制备而得:Preferably, the compound of formula (III) is prepared by protecting two hydroxyl groups and one amino group of the compound of formula (II) with a protecting group under basic conditions:

(II)。该式(II)化合物名称为7-Deaza-2’-deoxy-6-methoxyguanosine,CAS号:86392-74-7,分子式:C12H16N404,分子量:280.29。 (II). The name of the compound of formula (II) is 7-Deaza-2'-deoxy-6-methoxyguanosine, CAS number: 86392-74-7, molecular formula: C 12 H 16 N 4 0 4 , molecular weight: 280.29.

本发明还涉及一种7-去氮-7-丙炔胺-2’-去氧鸟嘌呤核苷酸的合成方法,所述方法包括由前述的方法合成得到的7-去氮-2’-脱氧-7-卤素取代鸟嘌呤核苷进一步合成所述7-去氮-7-丙炔胺-2’-去氧鸟嘌呤核苷酸。The present invention also relates to a method for synthesizing 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide, said method comprising 7-deaza-2'- Deoxy-7-halogen substituted guanosine to further synthesize the 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide.

优选的,包括如下步骤:Preferably, the following steps are included:

A、化合物dG(AP3)的合成:在CuI、Pd(PPh3)4(四(三苯基膦)钯)和TEA(三乙胺)存在的条件下,三氟乙酰丙炔胺和式(I)化合物反应,得化合物dG(AP3) A. Synthesis of compound dG(AP 3 ): in the presence of CuI, Pd(PPh 3 ) 4 (tetrakis(triphenylphosphine)palladium) and TEA (triethylamine), trifluoroacetylpropargylamine and formula (I) compound Reaction, get compound dG(AP3)

B、化合物dGTP(AP3)的合成:化合物dG(AP3)与三正丁胺焦磷酸盐(E-4)、2-氯-4H-1,3,2-苯并二氧磷-4-酮(E-3)在三乙胺和碘存在下反应,反应产物去保护,得化合物dGTP(AP3),即所述7-去氮-7-丙炔胺-2’-去氧鸟嘌呤核苷酸。B. Synthesis of compound dGTP (AP 3 ): compound dG (AP 3 ) and tri-n-butylamine pyrophosphate (E-4), 2-chloro-4H-1,3,2-benzodioxophosphorus-4 - Ketone (E-3) reacts in the presence of triethylamine and iodine, and the reaction product is deprotected to obtain the compound dGTP (AP 3 ), that is, the 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide.

优选的,步骤A中,所述式(I)化合物、三氟乙酰丙炔胺、CuI、Pd(PPh3)4和TEA的摩尔比为1:(2~3):0.072:0.025:(1.5~2)。Preferably, in step A, the molar ratio of the compound of formula (I), trifluoroacetylpropargylamine, CuI, Pd(PPh 3 ) 4 and TEA is 1: (2-3): 0.072: 0.025: (1.5 ~2).

优选的,步骤B中,所述三正丁胺焦磷酸盐、2-氯-4H-1,3,2-苯并二氧磷-4-酮和dG(AP3)的摩尔比为2:2:1。Preferably, in step B, the molar ratio of tri-n-butylamine pyrophosphate, 2-chloro-4H-1,3,2-benzodioxophosphor-4-one and dG(AP 3 ) is 2: 2:1.

本发明还涉及一种前述的合成方法制得的7-去氮-7-卤素取代鸟嘌呤核苷在合成7-去氮-7-丙炔胺-2’-去氧鸟嘌呤核苷酸中的用途。The present invention also relates to the 7-deaza-7-halogen substituted guanosine prepared by the aforementioned synthetic method in the synthesis of 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide the use of.

本发明具有如下有益效果:本发明合成了7-去氮-7-卤素-2’-去氧鸟嘌呤核苷(简称dG-X);该化合物是在DNA测序、标记、延伸等生物学领域广泛使用的基本原料,目前其销售价格很高,且合成方法复杂,难以控制。本发明的合成方法所需原料简单易得,合成过程均为常规化学反应,可用于大规模推广使用。The present invention has the following beneficial effects: the present invention synthesizes 7-deaza-7-halogen-2'-deoxyguanosine (abbreviated as dG-X); The widely used basic raw materials are currently sold at a high price, and the synthesis method is complicated and difficult to control. The raw materials required by the synthesis method of the present invention are simple and easy to obtain, and the synthesis process is all conventional chemical reactions, which can be used for large-scale popularization.

附图说明Description of drawings

通过阅读参照以下附图对非限制性实施例所作的详细描述,本发明的其它特征、目的和优点将会变得更明显:Other characteristics, objects and advantages of the present invention will become more apparent by reading the detailed description of non-limiting embodiments made with reference to the following drawings:

图1为7-去氮-7-碘-2’-去氧鸟嘌呤核苷(简称dG-I)的合成方法1的合成过程示意图。Fig. 1 is the synthesizing process schematic diagram of the synthetic method 1 of 7-deaza-7-iodo-2'-deoxyguanosine (abbreviated as dG-I).

图2为7-去氮-7-碘-2’-去氧鸟嘌呤核苷(简称dG-I)的合成方法2的合成过程示意图。Fig. 2 is the synthesizing process schematic diagram of the synthetic method 2 of 7-deaza-7-iodo-2'-deoxyguanosine (dG-I for short).

图3为7-去氮-7-碘鸟嘌呤核苷(简称G-I)合成过程示意图。3 is a schematic diagram of the synthesis process of 7-deaza-7-iodoguanosine (G-I for short).

图4为7-去氮-7-溴/氯-2’-去氧鸟嘌呤核苷(简称dG-G)合成过程示意图。Figure 4 is a schematic diagram of the synthesis process of 7-deaza-7-bromo/chloro-2'-deoxyguanosine (dG-G for short).

图5为7-去氮-7-碘-2’-去氧鸟嘌呤核苷dG-I在合成dGTP(AP3)中的用途。Figure 5 shows the use of 7-deaza-7-iodo-2'-deoxyguanosine dG-I in the synthesis of dGTP (AP 3 ).

图6为7-去氮-7-碘鸟嘌呤核苷G-I在合成GTP(AP3)中的用途。Fig. 6 is the use of 7-deaza-7-iodoguanosine GI in the synthesis of GTP (AP 3 ).

图7为7-去氮-7-碘-2’-去氧鸟嘌呤核苷dG-I的1H-NMR。Figure 7 is the 1H-NMR of 7-deaza-7-iodo-2'-deoxyguanosine dG-I.

图8为7-去氮-7-丙炔胺-2’-去氧鸟嘌呤核苷酸dGTP(AP3)的1H-NMR。Fig. 8 is 1 H-NMR of 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide dGTP (AP 3 ).

图9为7-去氮-7-丙炔胺-2’-去氧鸟嘌呤核苷酸dGTP(AP3)的31P-NMR。Fig. 9 is the 31 P-NMR of 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide dGTP (AP 3 ).

图10为7-去氮-7-丙炔胺-2’-去氧鸟嘌呤核苷酸dGTP(AP3)的HRMS谱图。Fig. 10 is the HRMS spectrum of 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide dGTP (AP 3 ).

具体实施方式detailed description

下面结合附图和具体实施例对本发明进行详细说明。以下实施例将有助于本领域的技术人员进一步理解本发明,但不以任何形式限制本发明。应当指出的是,对本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干调整和改进。这些都属于本发明的保护范围。本发明所用的原料、试剂均为市售AR、CP级。本发明所得中间产物及最终产物采用NMR等进行表征;The present invention will be described in detail below in conjunction with the accompanying drawings and specific embodiments. The following examples will help those skilled in the art to further understand the present invention, but do not limit the present invention in any form. It should be noted that those skilled in the art can make some adjustments and improvements without departing from the concept of the present invention. These all belong to the protection scope of the present invention. The raw materials and reagents used in the present invention are all commercially available AR and CP grades. The obtained intermediate product and final product of the present invention are characterized by NMR etc.;

实施例1、7-去氮-7-碘-2’-去氧鸟嘌呤核苷dG-I的合成方法之一One of the synthetic methods of embodiment 1,7-deaza-7-iodo-2'-deoxyguanosine dG-I

本实施例中dG-I的合成示意图如图1所示,具体合成方法分别包括如下步骤:The synthesis schematic diagram of dG-I in this embodiment is shown in Figure 1, and the specific synthesis method includes the following steps respectively:

步骤一、step one,

将化合物dG1-A(0.20g;0.714mmol)溶解于无水吡啶中,0℃下缓慢滴加新戊酰氯(0.75mL;7.14mmol),0℃下搅拌1h后,加入2ml甲醇,搅拌10min,旋出溶剂,加入乙酸乙酯(200ml)和饱和碳酸氢钠溶液(50ml)萃取,分离有机相,依次加入饱和碳酸氢钠溶液和饱和食盐水洗涤,无水硫酸钠干燥,旋出溶剂,硅胶柱层析[V(乙酸乙酯):V(石油醚)=1:1],得0.39g白色固体即化合物dG1-B,产率92%。1HNMR(400MHz,CD3OD)δ7.28(d,J=3.7Hz,1H),6.66(dd,J=5.9,8.6Hz,1H),6.51(d,J=3.7Hz,1H),5.41(m,1H),4.33-4.36(m,2H),4.22(m,1H),4.08(s,3H),2.83-2.96(m,2H),2.54-2.70(m,2H),2.48-2.54(ddd,J=2.0,5.9,14.2Hz,1H),1.15-1.23(m,27H).Dissolve compound dG 1 -A (0.20g; 0.714mmol) in anhydrous pyridine, slowly add pivaloyl chloride (0.75mL; 7.14mmol) dropwise at 0°C, stir at 0°C for 1h, add 2ml of methanol, and stir for 10min , spin out the solvent, add ethyl acetate (200ml) and saturated sodium bicarbonate solution (50ml) for extraction, separate the organic phase, add saturated sodium bicarbonate solution and saturated brine successively for washing, dry over anhydrous sodium sulfate, spin out the solvent, Silica gel column chromatography [V (ethyl acetate): V (petroleum ether) = 1: 1] gave 0.39 g of white solid, compound dG 1 -B, with a yield of 92%. 1 HNMR (400MHz, CD 3 OD) δ7.28(d, J=3.7Hz, 1H), 6.66(dd, J=5.9, 8.6Hz, 1H), 6.51(d, J=3.7Hz, 1H), 5.41 (m, 1H), 4.33-4.36(m, 2H), 4.22(m, 1H), 4.08(s, 3H), 2.83-2.96(m, 2H), 2.54-2.70(m, 2H), 2.48-2.54 (ddd, J=2.0, 5.9, 14.2Hz, 1H), 1.15-1.23(m, 27H).

步骤二、Step two,

将化合物dG1-B(0.42g;0.84mmol)溶于无水DMF中,剧烈搅拌下,加入4-碘代丁二酰亚胺(220mg;0.9mmol),室温搅拌22h,旋出溶剂,加入100ml乙醚和50ml碳酸氢钠溶液萃取,分离出有机相,饱和氯化钠洗涤,无水硫酸钠干燥,旋出溶剂,硅胶柱层析[V(乙酸乙酯):V(石油醚)=1:1],得0.5g白色固体即化合物dG1-C,产率91%。1H-NMR(400MHz,CD3OD)δ7.43(s,1H),6.63(dd,J=6.0,8.2Hz,1H),5.41(m,1H),4.33-4.36(m,2H),4.23(m,1H),4.09(s,3H),2.78-2.94(m,2H),2.57-2.70(m,2H),2.50-2.57(ddd,J=2.3,6.0,14.2Hz,1H),1.17-1.24(m,27H).The compound dG1-B (0.42g; 0.84mmol) was dissolved in anhydrous DMF, under vigorous stirring, 4-iodosuccinimide (220mg; 0.9mmol) was added, stirred at room temperature for 22h, the solvent was spun out, and 100ml was added Diethyl ether and 50ml sodium bicarbonate solution extraction, separate the organic phase, wash with saturated sodium chloride, dry over anhydrous sodium sulfate, spin off the solvent, silica gel column chromatography [V (ethyl acetate): V (petroleum ether) = 1: 1] to obtain 0.5 g of white solid, namely compound dG 1 -C, with a yield of 91%. 1 H-NMR (400MHz, CD 3 OD) δ7.43(s, 1H), 6.63(dd, J=6.0, 8.2Hz, 1H), 5.41(m, 1H), 4.33-4.36(m, 2H), 4.23(m, 1H), 4.09(s, 3H), 2.78-2.94(m, 2H), 2.57-2.70(m, 2H), 2.50-2.57(ddd, J=2.3, 6.0, 14.2Hz, 1H), 1.17-1.24(m, 27H).

步骤三、Step three,

将化合物dG1-C溶解于0.5M的甲醇/甲醇钠(10ml)中,65℃下搅拌12h,再加入10ml饱和碳酸氢钠溶液,继续搅拌10min,旋出甲醇,加入50ml乙酸乙酯萃取,有机层分别用饱和碳酸氢钠溶液和饱和氯化钠溶液洗涤,无水硫酸钠干燥,浓缩,残余物硅胶柱层析[V(甲醇):V(二氯甲烷)=1:10],得0.24g白色固体即化合物dG1-D,产率74%。1H-NMR(400MHz,CD3OD)δ7.17(s,1H),6.36(dd,J=6.0,8.4Hz,1H),4.47(m,1H),3.99(s,3H),3.96(m,1H),3.77(dd,J=3.4,12.0Hz,1H),3.70(dd,J=3.7,12.0Hz,1H),2.55-2.64(ddd,J=6.0,8.4,13.4Hz,1H),2.20-2.26(ddd,J=2.4,5.9,13.4Hz,1H)。Dissolve compound dG 1 -C in 0.5M methanol/sodium methoxide (10ml), stir at 65°C for 12h, then add 10ml of saturated sodium bicarbonate solution, continue stirring for 10min, spin out methanol, add 50ml of ethyl acetate for extraction, The organic layer was washed with saturated sodium bicarbonate solution and saturated sodium chloride solution respectively, dried over anhydrous sodium sulfate, concentrated, and the residue was subjected to silica gel column chromatography [V (methanol): V (dichloromethane) = 1: 10] to obtain 0.24 g of white solid is compound dG 1 -D, yield 74%. 1 H-NMR (400MHz, CD 3 OD) δ7.17(s, 1H), 6.36(dd, J=6.0, 8.4Hz, 1H), 4.47(m, 1H), 3.99(s, 3H), 3.96( m, 1H), 3.77(dd, J=3.4, 12.0Hz, 1H), 3.70(dd, J=3.7, 12.0Hz, 1H), 2.55-2.64(ddd, J=6.0, 8.4, 13.4Hz, 1H) , 2.20-2.26 (ddd, J=2.4, 5.9, 13.4Hz, 1H).

步骤四、Step four,

将化合物dG1-D置于氢氧化钠溶液(2N)中回流4h,冷却后加入2N盐酸溶液,调节溶液pH为6。浓缩,加入100ml二氯甲烷与甲醇混合液(V:V=1:1)洗涤,合并有机相,浓缩得255mg白色固体即dG-I,产率98%。dG-I的1H-NMR如图7所示,1HNMR(400MHz,MeOD)δ7.09(s,1H),6.35(dd,J=6.0Hz,J=8.0Hz,1H),4.42-4.44(m,1H),3.89-3.92(m,1H),3.65-3.74(m,2H),2.43-2.50(m,1H),2.19-2.24(m,1H).注:本方法同样适合7-去氮-7-溴和氯-2’-去氧鸟嘌呤核苷dG-Br/Cl的合成,不同之处在于第二步反应时,用NBS或BCS代替NIS即可,其它所有反应步骤和方法均相同。The compound dG 1 -D was placed in a sodium hydroxide solution (2N) and refluxed for 4 hours. After cooling, 2N hydrochloric acid solution was added to adjust the pH of the solution to 6. Concentrate, add 100ml of dichloromethane and methanol mixture (V:V=1:1) for washing, combine the organic phases, and concentrate to obtain 255mg of white solid, namely dG-I, with a yield of 98%. The 1 H-NMR of dG-I is shown in Figure 7, 1 HNMR (400MHz, MeOD) δ7.09 (s, 1H), 6.35 (dd, J=6.0Hz, J=8.0Hz, 1H), 4.42-4.44 (m, 1H), 3.89-3.92(m, 1H), 3.65-3.74(m, 2H), 2.43-2.50(m, 1H), 2.19-2.24(m, 1H). Note: This method is also suitable for 7- The synthesis of deaza-7-bromo and chloro-2'-deoxyguanosine dG-Br/Cl, the difference is that in the second step reaction, NBS or BCS can be used instead of NIS, and all other reaction steps and The methods are the same.

实施例2、7-去氮-7-碘-2’-去氧鸟嘌呤核苷dG-I的合成方法之二Embodiment 2, the second synthetic method of 7-deaza-7-iodo-2'-deoxyguanosine dG-I

本实施例中dG-I的合成示意图如图2所示,具体合成方法分别包括如下步骤:The synthesis schematic diagram of dG-I in this embodiment is shown in Figure 2, and the specific synthesis method includes the following steps respectively:

步骤一、step one,

将Sm-1(27.3g,138mmol)加入到70mL水中后,再加入3.0mL浓盐酸于90℃下搅拌0.5h,冷却至室温后加入醋酸钠(13.6g,165mmol)搅拌,将Sm-2(20.0g,159mmol)和醋酸钠(7.0g,85.4mmol)溶于150mL水中并加入到反应中,于80℃下搅拌2h后移至零摄氏度下搅拌1.5h,过滤,并用冰水及丙酮洗涤,抽干得15.4g,产率74%。1HNMR(400MHz,DMSO):δ=10.94(s,1H),10.35(s,1H),6.58(dd,J=3.4,2.2Hz,1H),6.15(dd,J=3.4,2.1Hz,1H),6.09(s,2H).After Sm-1 (27.3g, 138mmol) was added to 70mL of water, 3.0mL of concentrated hydrochloric acid was added and stirred at 90°C for 0.5h. After cooling to room temperature, sodium acetate (13.6g, 165mmol) was added and stirred, and Sm-2 ( 20.0g, 159mmol) and sodium acetate (7.0g, 85.4mmol) were dissolved in 150mL water and added to the reaction, stirred at 80°C for 2h, then moved to zero°C and stirred for 1.5h, filtered, and washed with ice water and acetone, It was sucked dry to obtain 15.4 g, and the yield was 74%. 1 HNMR (400MHz, DMSO): δ=10.94(s, 1H), 10.35(s, 1H), 6.58(dd, J=3.4, 2.2Hz, 1H), 6.15(dd, J=3.4, 2.1Hz, 1H ), 6.09(s, 2H).

步骤二、Step two,

将G005(10.0g,66.6mmol)加入到100mLPOCl3中,回流2h,冷却至室温后旋除溶剂后,将120mL冰水加入到反应中,并将固体过滤,将滤液用氨水调节至PH=2,并将沉淀物至于冰浴中2h后过滤,过滤的固体第一次用10mL冰水洗涤,第二次用30mL冰乙醚洗涤,抽干后得8.7g,产率78%。1HNMR(400MHz,DMSO):δ=11.43(s,1H,NH),7.07(d,1H,NHCHCH),6.46(s,2H,NH2),6.22(d,1H,CHNH)。Add G005 (10.0g, 66.6mmol) into 100mL POCl 3 , reflux for 2h, cool to room temperature and spin off the solvent, add 120mL ice water to the reaction, filter the solid, and adjust the filtrate to pH=2 with ammonia water , and the precipitate was placed in an ice bath for 2 hours and then filtered. The filtered solid was washed with 10 mL of ice water for the first time, and washed with 30 mL of ice ether for the second time. After drying, 8.7 g was obtained, with a yield of 78%. 1 H NMR (400 MHz, DMSO): δ=11.43 (s, 1H, NH), 7.07 (d, 1H, NHCHCH), 6.46 (s, 2H, NH2), 6.22 (d, 1H, CHNH).

步骤三、Step three,

将G006(8.5g,50.42mmol)加入到120mL无水吡啶中,再加入新戊酰氯(21.68mL,176.20mmol)并于室温下搅拌2h后旋除溶剂,溶于1.7L二氯甲烷,有机相用0.1M盐酸溶液(2*350mL)洗涤后,旋除溶剂后柱层析DCM:MeOH10:1得8.15g,产率64%。1HNMR(400MHz,[D6]-DMSO):δ=9.98(s,1H,NHC(0)),7.50(d,J=3.6Hz,1H,NHCHCH),6.49(d,J=3.6Hz,1H,CHNH),1.20(s,9H,C(CH3)3)。G006 (8.5g, 50.42mmol) was added to 120mL of anhydrous pyridine, then pivaloyl chloride (21.68mL, 176.20mmol) was added and stirred at room temperature for 2h, then the solvent was removed, dissolved in 1.7L of dichloromethane, organic phase After washing with 0.1M hydrochloric acid solution (2*350mL), spin off the solvent and perform column chromatography DCM:MeOH10:1 to obtain 8.15g, yield 64%. 1 HNMR (400MHz, [D6]-DMSO): δ=9.98(s, 1H, NHC(0)), 7.50(d, J=3.6Hz, 1H, NHCHCH), 6.49(d, J=3.6Hz, 1H , CHNH), 1.20 (s, 9H, C(CH3)3).

步骤四、Step four,

将G007(3.10g,12.27mmol)溶于60mLTHF中,氮气保护,锡箔纸包裹后,加入NIS(3.04g,13.51mmol)于室温下搅拌1h,加入500mLDCM,用200mL水洗涤,旋除溶剂后,柱层析DCM:Me0H99:1得3.76g,产率81%。1HNMR(400MHz,DMSO):δ=12.65(s,1H,CHNH),10.06(s,1H,NHC(0)),7.73(d,J=2.4Hz,1H,CH),1.19(s,9H,C(CH3)3)。G007 (3.10g, 12.27mmol) was dissolved in 60mLTHF, protected by nitrogen, wrapped in foil paper, added NIS (3.04g, 13.51mmol) and stirred at room temperature for 1h, added 500mL of DCM, washed with 200mL of water, and after the solvent was removed, Column chromatography DCM:MeOH99:1 yielded 3.76g, yield 81%. 1 HNMR (400MHz, DMSO): δ=12.65(s, 1H, CHNH), 10.06(s, 1H, NHC(0)), 7.73(d, J=2.4Hz, 1H, CH), 1.19(s, 9H , C(CH 3 ) 3 ).

步骤五、Step five,

将G008(1.5g,4.0mmol)和硫酸铵(15mg,0.11mmol)在六甲基二硅氮烷(15mL,72.76mmol)中回流20h于氩气的保护中,旋除溶剂后加入40mL二氯乙烷,加入Sm-1(2.304,6.0mmol)和TMSOTf(1.25mL,6.47mmol)并于室温下搅拌至澄清后于50摄氏度下搅拌24h,加入60mLDCM,并用30mL饱和碳酸氢钠和饱和食盐水洗涤,旋除有机相后,柱层析得1.48g,产率45%。1HNMR(400MHz,D6-DMSO):δ=10.29(s,1H),8.02(s,1H,),7.90-7.41(m,10H),6.35(s,1H),6.26(d,J=0.8Hz,1H),4.27(s,1H),3.75(s,1H),3.49(t,J=0.8Hz,1H),2.35-2.28(m,1H),2.09-2.01(m,1H),1.15(s,9H).G008 (1.5g, 4.0mmol) and ammonium sulfate (15mg, 0.11mmol) were refluxed in hexamethyldisilazane (15mL, 72.76mmol) for 20h under the protection of argon, and 40mL of dichloro Ethane, add Sm-1 (2.304, 6.0mmol) and TMSOTf (1.25mL, 6.47mmol) and stir at room temperature until clear, then stir at 50°C for 24h, add 60mL DCM, and wash with 30mL saturated sodium bicarbonate and saturated saline After washing and spinning off the organic phase, 1.48 g was obtained by column chromatography with a yield of 45%. 1 HNMR (400MHz, D6-DMSO): δ=10.29(s, 1H), 8.02(s, 1H,), 7.90-7.41(m, 10H), 6.35(s, 1H), 6.26(d, J=0.8 Hz, 1H), 4.27(s, 1H), 3.75(s, 1H), 3.49(t, J=0.8Hz, 1H), 2.35-2.28(m, 1H), 2.09-2.01(m, 1H), 1.15 (s, 9H).

步骤六、Step six,

将G009(1.056g,1.5mmol)加入到0.5MMeONa/MeOH(20.0mL)中,回流3h后用冰醋酸中和至中性后柱层析DCM:MeOH5:1得化合物dG1-D490mg,产率80%。1H-NMR(400MHz,CD3OD)δ7.17(s,1H),6.36(dd,J=6.0,8.4Hz,1H),4.47(m,1H),3.99(s,3H),3.96(m,1H),3.77(dd,J=3.4,12.0Hz,1H),3.70(dd,J=3.7,12.0Hz,1H),2.55-2.64(ddd,J=6.0,8.4,13.4Hz,1H),2.20-2.26(ddd,J=2.4,5.9,13.4Hz,1H)。G009 (1.056g, 1.5mmol) was added to 0.5MMeONa/MeOH (20.0mL), refluxed for 3h, neutralized to neutral with glacial acetic acid, followed by column chromatography DCM:MeOH5:1 to obtain 490mg of compound dG1-D, yield 80 %. 1 H-NMR (400MHz, CD 3 OD) δ7.17(s, 1H), 6.36(dd, J=6.0, 8.4Hz, 1H), 4.47(m, 1H), 3.99(s, 3H), 3.96( m, 1H), 3.77(dd, J=3.4, 12.0Hz, 1H), 3.70(dd, J=3.7, 12.0Hz, 1H), 2.55-2.64(ddd, J=6.0, 8.4, 13.4Hz, 1H) , 2.20-2.26 (ddd, J=2.4, 5.9, 13.4Hz, 1H).

步骤七、Step seven,

将化合物dG1-D置于氢氧化钠溶液(2N)中回流4h,冷却后加入2N盐酸溶液,调节溶液pH为6。浓缩,加入100ml二氯甲烷与甲醇混合液(V:V=1:1)洗涤,合并有机相,浓缩得255mg白色固体即dG-I,产率98%。1HNMR(400MHz,MeOD)δ7.09(s,1H),6.35(dd,J=6.0Hz,J=8.0Hz,1H),4.42-4.44(m,1H),3.89-3.92(m,1H),3.65-3.74(m,2H),2.43-2.50(m,1H),2.19-2.24(m,1H).注:本方法同样适合7-去氮-7-溴和氯-2’-去氧鸟嘌呤核苷dG-Br/Cl的合成,不同之处在于第四步反应时,用NBS或BCS代替NIS即可,其它所有反应步骤和方法均相同。The compound dG 1 -D was placed in a sodium hydroxide solution (2N) and refluxed for 4 hours. After cooling, 2N hydrochloric acid solution was added to adjust the pH of the solution to 6. Concentrate, add 100ml of dichloromethane and methanol mixture (V:V=1:1) for washing, combine the organic phases, and concentrate to obtain 255mg of white solid, namely dG-I, with a yield of 98%. 1 HNMR (400MHz, MeOD) δ7.09(s, 1H), 6.35(dd, J=6.0Hz, J=8.0Hz, 1H), 4.42-4.44(m, 1H), 3.89-3.92(m, 1H) , 3.65-3.74 (m, 2H), 2.43-2.50 (m, 1H), 2.19-2.24 (m, 1H). Note: This method is also suitable for 7-deaza-7-bromo and chloro-2'-deoxy The difference in the synthesis of guanosine dG-Br/Cl is that in the fourth step, NBS or BCS can be used instead of NIS, and all other reaction steps and methods are the same.

实施例3、7-去氮-7-碘-鸟嘌呤核苷G-I的合成方法The synthetic method of embodiment 3,7-deaza-7-iodine-guanosine G-I

本实施例中G-I的合成示意图如图3所示,具体合成方法分别包括如下步骤:The synthesizing schematic diagram of G-I in the present embodiment is as shown in Figure 3, and specific synthesizing method comprises the following steps respectively:

步骤一、step one,

将G008(1.5g,4.0mmol)和硫酸铵(15mg,0.11mmo1)在六甲基二硅氮烷(15mL,72.76mmol)中回流20h于氩气的保护中,旋除溶剂后加入40mL二氯乙烷,加入G-I-0(6.0mmol)和TMSOTf(1.25mL,6.47mmol)并于室温下搅拌至澄清后于50摄氏度下搅拌24h,加入60mLDCM,并用30mL饱和碳酸氢钠和饱和食盐水洗涤,旋除有机相后,柱层析得G-I-B化合物1.6g。1HNMR(600MHz,DMSO):δ=10.29(s,1H),8.02(s,1H),7.91-7.85(m,6H),7.64-7.58(m,3H),7.46-7.39(m,6H),6.48(d,J=3.9Hz,1H),6.41(t,J=6.1,6.1Hz,1H),6.32(dd,J=6.0,4.0Hz,1H),4.82(dd,J=10.7,5.0Hz,1H),4.75(dd,J=11.8,4.4Hz,1H),4.63(dd,J=11.8,5.7Hz,1H),1.15(s,9H)。Reflux G008 (1.5g, 4.0mmol) and ammonium sulfate (15mg, 0.11mmol) in hexamethyldisilazane (15mL, 72.76mmol) for 20h under the protection of argon, spin off the solvent and add 40mL of dichloro Ethane, add G-I-0 (6.0mmol) and TMSOTf (1.25mL, 6.47mmol) and stir at room temperature until clear, then stir at 50°C for 24h, add 60mL DCM, and wash with 30mL saturated sodium bicarbonate and saturated brine, After spinning off the organic phase, 1.6 g of G-I-B compound was obtained by column chromatography. 1HNMR (600MHz, DMSO): δ=10.29(s, 1H), 8.02(s, 1H), 7.91-7.85(m, 6H), 7.64-7.58(m, 3H), 7.46-7.39(m, 6H), 6.48(d, J=3.9Hz, 1H), 6.41(t, J=6.1, 6.1Hz, 1H), 6.32(dd, J=6.0, 4.0Hz, 1H), 4.82(dd, J=10.7, 5.0Hz , 1H), 4.75(dd, J=11.8, 4.4Hz, 1H), 4.63(dd, J=11.8, 5.7Hz, 1H), 1.15(s, 9H).

步骤二、Step two,

将G-I-B(1.056g,1.5mmol)加入到0.5MMeONa/MeOH(20.0mL)中,回流3h后用冰醋酸中和至中性后柱层析DCM:MeOH5:1得G-I-A化合物490mg,产率80%。1H-NMR(DMSO-d6,250MHz):δ3.49-3.57(m,2H,H-C(5’)),3.80-3.82(m,1H,H-C(4’)),3.93(s,3H,OMe),4.01-4.03(m,1H,H-C(3’)),4.23-4.28(m,1H,H-C(2’)),5.01(t,J=5.5Hz,1H,0H-C(5’)),5.05(d,J=4.4Hz,1H,0H-C(3’)),5.25(d,J=6.2Hz,1H,0H-C(2’)),5.94(d,J=6.5Hz,1H,H-C(1’)),6.38(s,2H,NH2),7.31(s,1H,H-C(6)).G-I-B (1.056g, 1.5mmol) was added to 0.5MMeONa/MeOH (20.0mL), refluxed for 3h, neutralized to neutral with glacial acetic acid, followed by column chromatography DCM:MeOH5:1 to obtain 490mg of G-I-A compound, yield 80% . 1H-NMR (DMSO-d6, 250MHz): δ3.49-3.57(m, 2H, H-C(5')), 3.80-3.82(m, 1H, H-C(4')), 3.93(s, 3H, OMe ), 4.01-4.03(m, 1H, H-C(3')), 4.23-4.28(m, 1H, H-C(2')), 5.01(t, J=5.5Hz, 1H, 0H-C(5') ), 5.05(d, J=4.4Hz, 1H, 0H-C(3')), 5.25(d, J=6.2Hz, 1H, 0H-C(2')), 5.94(d, J=6.5Hz , 1H, H-C(1')), 6.38(s, 2H, NH2), 7.31(s, 1H, H-C(6)).

步骤三、Step three,

将化合物G-I-A置于氢氧化钠溶液(2N)中回流4h,冷却后加入2N盐酸溶液,调节溶液pH为6。浓缩,加入100ml二氯甲烷与甲醇混合液(V:V=1:1)洗涤,合并有机相,浓缩得255mg白色固体即G-I,产率98%。1HNMR(600MHz,DMSO):4.99(brs,1H,5’-OH),5.04(d,1H,J=3.2,3’-OH),5.26(d,1H,J=5.9,2’-OH),6.33(s,2H,NH2),7.14(s,1H,6-H),10.48(s,1H,NH).注:本方法同样适合7-去氮-7-溴和氯鸟嘌呤核苷G-Br/Cl的合成,不同之处在于第一步反应所用的原料G008的鸟嘌呤碱基的7位是溴或氯即可,其它所有反应步骤和方法均相同。Compound G-I-A was placed in sodium hydroxide solution (2N) and refluxed for 4 h, and after cooling, 2N hydrochloric acid solution was added to adjust the pH of the solution to 6. Concentrate, add 100ml of dichloromethane and methanol mixture (V:V=1:1) for washing, combine the organic phases, and concentrate to obtain 255mg of white solid, namely G-I, with a yield of 98%. 1HNMR (600MHz, DMSO): 4.99 (brs, 1H, 5'-OH), 5.04 (d, 1H, J=3.2, 3'-OH), 5.26 (d, 1H, J=5.9, 2'-OH) , 6.33(s, 2H, NH2), 7.14(s, 1H, 6-H), 10.48(s, 1H, NH). Note: This method is also suitable for 7-deaza-7-bromo and chloroguanosine The difference in the synthesis of G-Br/Cl is that the 7-position of the guanine base of the raw material G008 used in the first step reaction can be bromine or chlorine, and all other reaction steps and methods are the same.

实施例4、7-去氮-7-溴/氯-2-脱氧鸟嘌呤核苷dG-I的合成方法之一One of the synthetic methods of embodiment 4, 7-deaza-7-bromo/chloro-2-deoxyguanosine dG-I

本实施例中dG-G的合成示意图如图4所示,具体合成方法分别包括如下步骤:The synthesis schematic diagram of dG-G in this embodiment is shown in Figure 4, and the specific synthesis method includes the following steps respectively:

步骤一、step one,

将化合物dG1-A(0.20g;0.714mmol)溶解于无水吡啶中,0℃下缓慢滴加新戊酰氯(0.75mL;7.14mmol),0℃下搅拌1h后,加入2ml甲醇,搅拌10min,旋出溶剂,加入乙酸乙酯(200ml)和饱和碳酸氢钠溶液(50ml)萃取,分离有机相,依次加入饱和碳酸氢钠溶液和饱和食盐水洗涤,无水硫酸钠干燥,旋出溶剂,硅胶柱层析[V(乙酸乙酯):V(石油醚)=1:1],得0.39g白色固体即化合物dG1-B,产率92%。1HNMR(400MHz,CD3OD)δ7.28(d,J=3.7Hz,1H),6.66(dd,J=5.9,8.6Hz,1H),6.51(d,J=3.7Hz,1H),5.41(m,1H),4.33-4.36(m,2H),4.22(m,1H),4.08(s,3H),2.83-2.96(m,2H),2.54-2.70(m,2H),2.48-2.54(ddd,J=2.0,5.9,14.2Hz,1H),1.15-1.23(m,27H).Compound dG1-A (0.20g; 0.714mmol) was dissolved in anhydrous pyridine, pivaloyl chloride (0.75mL; 7.14mmol) was slowly added dropwise at 0°C, stirred at 0°C for 1h, 2ml of methanol was added, and stirred for 10min, Spin out the solvent, add ethyl acetate (200ml) and saturated sodium bicarbonate solution (50ml) for extraction, separate the organic phase, add saturated sodium bicarbonate solution and saturated brine successively to wash, dry over anhydrous sodium sulfate, spin out the solvent, silica gel Column chromatography [V (ethyl acetate): V (petroleum ether) = 1: 1] gave 0.39 g of white solid, compound dG 1 -B, with a yield of 92%. 1 HNMR (400MHz, CD 3 OD) δ7.28(d, J=3.7Hz, 1H), 6.66(dd, J=5.9, 8.6Hz, 1H), 6.51(d, J=3.7Hz, 1H), 5.41 (m, 1H), 4.33-4.36(m, 2H), 4.22(m, 1H), 4.08(s, 3H), 2.83-2.96(m, 2H), 2.54-2.70(m, 2H), 2.48-2.54 (ddd, J=2.0, 5.9, 14.2Hz, 1H), 1.15-1.23(m, 27H).

步骤二、Step two,

将化合物dG1-B(0.42g;0.84mmol)溶于无水DMF中,剧烈搅拌下,加入4-溴代丁二酰亚胺或者4-氯代丁二酰亚胺(220mg;0.9mmol),室温搅拌22h,旋出溶剂,加入100ml乙醚和50ml碳酸氢钠溶液萃取,分离出有机相,饱和氯化钠洗涤,无水硫酸钠干燥,旋出溶剂,硅胶柱层析[V(乙酸乙酯):V(石油醚)=1:1],得0.5g白色固体即化合物dG1-E,产率91%。1H-NMR(400MHz,CD3OD)δ7.43(s,1H),6.63(dd,J=6.0,8.2Hz,1H),5.41(m,1H),4.33-4.36(m,2H),4.23(m,1H),4.09(s,3H),2.78-2.94(m,2H),2.57-2.70(m,2H),2.50-2.57(ddd,J=2.3,6.0,14.2Hz,1H),1.17-1.24(m,27H).Compound dG 1 -B (0.42g; 0.84mmol) was dissolved in anhydrous DMF, under vigorous stirring, 4-bromosuccinimide or 4-chlorosuccinimide (220mg; 0.9mmol) was added , stir at room temperature for 22h, spin out the solvent, add 100ml ether and 50ml sodium bicarbonate solution for extraction, separate the organic phase, wash with saturated sodium chloride, dry over anhydrous sodium sulfate, spin out the solvent, silica gel column chromatography [V (ethyl acetate ester): V (petroleum ether) = 1:1] to obtain 0.5 g of white solid, compound dG 1 -E, with a yield of 91%. 1 H-NMR (400MHz, CD 3 OD) δ7.43(s, 1H), 6.63(dd, J=6.0, 8.2Hz, 1H), 5.41(m, 1H), 4.33-4.36(m, 2H), 4.23(m, 1H), 4.09(s, 3H), 2.78-2.94(m, 2H), 2.57-2.70(m, 2H), 2.50-2.57(ddd, J=2.3, 6.0, 14.2Hz, 1H), 1.17-1.24(m, 27H).

步骤三、Step three,

将化合物dG1-E溶解于0.5M的甲醇/甲醇钠(10ml)中,65℃下搅拌12h,再加入10ml饱和碳酸氢钠溶液,继续搅拌10min,旋出甲醇,加入50ml乙酸乙酯萃取,有机层分别用饱和碳酸氢钠溶液和饱和氯化钠溶液洗涤,无水硫酸钠干燥,浓缩,残余物硅胶柱层析[V(甲醇):V(二氯甲烷)=1:10],得0.24g白色固体即化合物dG1-F,产率74%。1H-NMR(400MHz,CD3OD)δ7.17(s,1H),6.36(dd,J=6.0,8.4Hz,1H),4.47(m,1H),3.99(s,3H),3.96(m,1H),3.77(dd,J=3.4,12.0Hz,1H),3.70(dd,J=3.7,12.0Hz,1H),2.55-2.64(ddd,J=6.0,8.4,13.4Hz,1H),2.20-2.26(ddd,J=2.4,5.9,13.4Hz,1H)。Dissolve compound dG1-E in 0.5M methanol/sodium methoxide (10ml), stir at 65°C for 12h, then add 10ml of saturated sodium bicarbonate solution, continue stirring for 10min, spin out methanol, add 50ml of ethyl acetate to extract, organic The layers were washed with saturated sodium bicarbonate solution and saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated, and the residue was subjected to silica gel column chromatography [V (methanol): V (dichloromethane) = 1: 10] to obtain 0.24 g white solid is the compound dG 1 -F, the yield is 74%. 1 H-NMR (400MHz, CD 3 OD) δ7.17(s, 1H), 6.36(dd, J=6.0, 8.4Hz, 1H), 4.47(m, 1H), 3.99(s, 3H), 3.96( m, 1H), 3.77(dd, J=3.4, 12.0Hz, 1H), 3.70(dd, J=3.7, 12.0Hz, 1H), 2.55-2.64(ddd, J=6.0, 8.4, 13.4Hz, 1H) , 2.20-2.26 (ddd, J=2.4, 5.9, 13.4Hz, 1H).

步骤四、Step four,

将化合物dG1-F置于氢氧化钠溶液(2N)中回流4h,冷却后加入2N盐酸溶液,调节溶液pH为6。浓缩,加入100ml二氯甲烷与甲醇混合液(V:V=1:1)洗涤,合并有机相,浓缩得255mg白色固体即dG1-G,产率98%。1HNMR(400MHz,MeOD)δ7.09(s,1H),6.35(dd,J=6.0Hz,J=8.0Hz,1H),4.42-4.44(m,1H),3.89-3.92(m,1H),3.65-3.74(m,2H),2.43-2.50(m,1H),2.19-2.24(m,1H).The compound dG 1 -F was placed in a sodium hydroxide solution (2N) and refluxed for 4 hours. After cooling, 2N hydrochloric acid solution was added to adjust the pH of the solution to 6. Concentrate, add 100ml of dichloromethane and methanol mixture (V:V=1:1) for washing, combine the organic phases, and concentrate to obtain 255mg of white solid, namely dG 1 -G, with a yield of 98%. 1 HNMR (400MHz, MeOD) δ7.09(s, 1H), 6.35(dd, J=6.0Hz, J=8.0Hz, 1H), 4.42-4.44(m, 1H), 3.89-3.92(m, 1H) , 3.65-3.74(m, 2H), 2.43-2.50(m, 1H), 2.19-2.24(m, 1H).

实施例5、7-去氮-7-碘-2’-脱氧鸟嘌呤核苷dG-I在合成dGTP(APExample 5, 7-deaza-7-iodo-2'-deoxyguanosine dG-I in the synthesis of dGTP (AP 33 )中的用途) uses in

本实施例中dGTP(AP3)的合成示意图如图5所示,具体合成方法分别包括如下步骤:The synthesizing schematic diagram of dGTP (AP3) in the present embodiment is shown in Figure 5, and specific synthesizing method comprises the following steps respectively:

步骤一、step one,

向一单口瓶中加入化合物dG-I(0.25g,0.4mmol),再称取CuI(22mg;1mmol)和Pd(PPh3)4(48mg;0.04mmol)加入反应瓶中,抽真空,氮气保护,铝箔包裹,加入10mlDMF,搅拌溶解,注入TEA(0.088g;0.8mmol)和三氟乙酰丙炔胺(0.2g;1.2mmol),50℃搅拌13小时后,反应结束,旋出溶剂,将残余物溶于100ml乙酸乙酯,依次用饱和碳酸氢钠溶液和饱和氯化钠溶液洗涤,无水硫酸钠干燥,浓缩,柱层析[V(乙酸乙酯):V(正己烷)=1:3],得0.1g白色固体即dG(AP3),产率39%。1HNMR(400MHz,MeOD)δ7.25(s,1H),6.38-6.42(m,1H),4.47-4.50(m,1H),4.33(s,2H),3.96(dd,J=3.6Hz,J=6.8Hz,1H),3.70-3.80(m,2H),2.48-2.55(m,1H),2.26-2.32(m,1H).Add compound dG-I (0.25g, 0.4mmol) to a single-necked flask, then weigh CuI (22mg; 1mmol) and Pd(PPh3)4 (48mg; 0.04mmol) into the reaction flask, vacuumize, nitrogen protection, Wrap in aluminum foil, add 10ml of DMF, stir to dissolve, inject TEA (0.088g; 0.8mmol) and trifluoroacetylpropargylamine (0.2g; 1.2mmol), stir at 50°C for 13 hours, the reaction is over, spin out the solvent, and the residue Dissolve in 100ml ethyl acetate, wash with saturated sodium bicarbonate solution and saturated sodium chloride solution successively, dry over anhydrous sodium sulfate, concentrate, column chromatography [V (ethyl acetate): V (n-hexane) = 1:3 ] to obtain 0.1 g of white solid, ie, dG(AP 3 ), with a yield of 39%. 1 HNMR (400MHz, MeOD) δ7.25(s, 1H), 6.38-6.42(m, 1H), 4.47-4.50(m, 1H), 4.33(s, 2H), 3.96(dd, J=3.6Hz, J=6.8Hz, 1H), 3.70-3.80(m, 2H), 2.48-2.55(m, 1H), 2.26-2.32(m, 1H).

步骤二、Step two,

将化合物dG(AP3)真空干燥12h,在手套箱中分别称取化合物dG(AP3)(30mg,0.072mmol)、三正丁胺焦磷酸盐(80mg,0.145mmol)、2-氯-4H-1,3,2-苯并二氧磷-4-酮(30mg,0.15mmol)置于三个反应管中。将三正丁胺焦磷酸盐溶于0.25mL无水DMF中,再加入0.3mL新蒸的三正丁胺,常温搅拌半小时后,把反应液注入2-氯-4H-1,3,2-苯并二氧磷-4-酮的无水DMF(0.25mL)溶液中,常温搅拌半小时。然后将该混合液注入到2中,搅拌1.5h。加入1mL3%碘(9:1Py/H20)溶液,保持碘液颜色15min不退色。15min后加入2mL水,2h后,加入0.75mL3MNaCl溶液、20mL无水乙醇,-20℃冷冻12h,离心(20min,3200rpm)。倾去上清液,沉淀抽干溶剂后,加入浓氨水,室温搅拌5小时。减压旋出溶剂,出现棕色固体,RP-HPLC分析[条件:柱子:C18,5μm,4.6×250mm;流速:1mL/min;流动相:20mMTEAA和EtOH,0-20%EtOH(35min),可见检测器波长:650nm],保留时间t=18min。RP-HPLC分离[条件:柱子:C18,5μm,9.4×250mm;流速:4mL/min;流动相:20mMTEAA和MeOH,0-15%MeOH(25min),紫外检测器波长:254nm],保留时间t=15min。NaCl/EtOH除去乙酸三乙胺盐,得12mg白色固体即dGTP(AP3)。产率26%。dGTP(AP3)的1H-NMR、31P-NMR、HRMS谱图分别如图8、9、10所示,1HNMR(400MHz,D2O)δ7.45(s,1H),6.34(t,J=6.8Hz,1H),4.73(s,1H),4.11-4.20(m,3H),4.06(s,2H),2.53-2.58(m,1H),2.41-2.46(m,1H);31PNMR(D2O,162MHz):-10.59(t,J=9.9Hz,1P),-11.24(d,J=17.3Hz,1P),-22.98(d,J=20.7Hz,1P).ESI-HRMS:calcforC14H19N5O13P3[M-H]-558.0192,found558.0179.注:本方法同样适合7-去氮-7-溴/氯-2’-脱氧鸟嘌呤核苷dG-Br/Cl在合成dGTP(AP3)中的用途,不同之处在于第一步反应时,用dG-Br/Cl代替dG-I即可,其它所有反应步骤和方法均相同。Compound dG(AP 3 ) was vacuum-dried for 12 hours, and compound dG(AP 3 ) (30mg, 0.072mmol), tri-n-butylamine pyrophosphate (80mg, 0.145mmol), 2-chloro-4H - 1,3,2-Benzophosphor-4-one (30 mg, 0.15 mmol) was placed in three reaction tubes. Dissolve tri-n-butylamine pyrophosphate in 0.25 mL of anhydrous DMF, then add 0.3 mL of freshly distilled tri-n-butylamine, stir at room temperature for half an hour, inject the reaction solution into 2-chloro-4H-1,3,2 - in anhydrous DMF (0.25 mL) solution of benzodioxophosphor-4-one, stirred at room temperature for half an hour. Then the mixture was injected into 2 and stirred for 1.5h. Add 1 mL of 3% iodine (9:1 Py/H20) solution, and keep the color of the iodine solution for 15 minutes without fading. After 15 min, 2 mL of water was added, and after 2 h, 0.75 mL of 3M NaCl solution and 20 mL of absolute ethanol were added, frozen at -20°C for 12 h, and centrifuged (20 min, 3200 rpm). Pour off the supernatant, drain the solvent after the precipitation, add concentrated ammonia water, and stir at room temperature for 5 hours. The solvent was spinned out under reduced pressure, and a brown solid appeared, analyzed by RP-HPLC [conditions: column: C18, 5 μm, 4.6 × 250 mm; flow rate: 1 mL/min; mobile phase: 20 mM TEAA and EtOH, 0-20% EtOH (35 min), visible Detector wavelength: 650nm], retention time t=18min. RP-HPLC separation [conditions: column: C18, 5μm, 9.4×250mm; flow rate: 4mL/min; mobile phase: 20mM TEAA and MeOH, 0-15% MeOH (25min), UV detector wavelength: 254nm], retention time t =15min. NaCl/EtOH was used to remove the triethylamine acetate salt to obtain 12 mg of white solid, dGTP(AP 3 ). Yield 26%. The 1 H-NMR, 31 P-NMR, and HRMS spectra of dGTP(AP3) are shown in Figures 8, 9, and 10, respectively. 1 HNMR (400MHz, D 2 O) δ7.45(s, 1H), 6.34(t , J=6.8Hz, 1H), 4.73(s, 1H), 4.11-4.20(m, 3H), 4.06(s, 2H), 2.53-2.58(m, 1H), 2.41-2.46(m, 1H); 31 PNMR (D 2 O, 162MHz): -10.59(t, J=9.9Hz, 1P), -11.24(d, J=17.3Hz, 1P), -22.98(d, J=20.7Hz, 1P).ESI -HRMS: calcforC 14 H 19 N 5 O 13 P 3 [MH] - 558.0192, found558.0179. Note: This method is also suitable for 7-deaza-7-bromo/chloro-2'-deoxyguanosine dG- The use of Br/Cl in the synthesis of dGTP (AP3) is different in that in the first step of the reaction, dG-Br/Cl can be used instead of dG-I, and all other reaction steps and methods are the same.

实施例6、7-去氮-7-碘鸟嘌呤核苷G-I在合成G(APEmbodiment 6, 7-deaza-7-iodine guanosine G-I is synthesizing G(AP 33 )中的用途) uses in

本实施例中G(AP3)的合成示意图如图6所示,具体合成方法分别包括如下步骤:The schematic diagram of the synthesis of G(AP 3 ) in this example is shown in Figure 6, and the specific synthesis method includes the following steps:

向一单口瓶中加入化合物G-I(0.25g,0.4mmol),再称取CuI(22mg;1mmol)和Pd(PPh3)4(48mg;0.04mmol)加入反应瓶中,抽真空,氮气保护,铝箔包裹,加入10mlDMF,搅拌溶解,注入TEA(0.088g;0.8mmol)和三氟乙酰丙炔胺(0.2g;1.2mmol),50℃搅拌13小时后,反应结束,旋出溶剂,将残余物溶于100ml乙酸乙酯,依次用饱和碳酸氢钠溶液和饱和氯化钠溶液洗涤,无水硫酸钠干燥,浓缩,柱层析[V(乙酸乙酯):V(正己烷)=1:3],得0.1g白色固体即G(AP3),产率39%。1HNMR(400MHz,CDCl3)δ7.24(s,1H),6.38(t,J=0.8Hz,1H),4.49-4.46(m,1H),4.31(s,2H),3.94(d,J=1.6Hz,1H),3.78-3.68(m,1H),3.54-2.47(m,1H),2.3-2.24(m,1H).注:本方法同样适合7-去氮-7-碘鸟嘌呤核苷G-I在合成G(AP3)中的用途,不同之处在于第一步反应时,用G-Br/Cl代替G-I即可,其它所有反应步骤和方法均相同。Add compound GI (0.25g, 0.4mmol) to a single-necked flask, then weigh CuI (22mg; 1mmol) and Pd(PPh 3 ) 4 (48mg; 0.04mmol) into the reaction flask, vacuumize, nitrogen protection, aluminum foil Wrap, add 10ml of DMF, stir to dissolve, inject TEA (0.088g; 0.8mmol) and trifluoroacetylpropargylamine (0.2g; 1.2mmol), stir at 50°C for 13 hours, the reaction is over, spin out the solvent, and dissolve the residue In 100ml of ethyl acetate, washed successively with saturated sodium bicarbonate solution and saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated, column chromatography [V (ethyl acetate): V (n-hexane) = 1:3] , to obtain 0.1 g of white solid, namely G(AP 3 ), with a yield of 39%. 1 HNMR (400MHz, CDCl 3 ) δ7.24(s, 1H), 6.38(t, J=0.8Hz, 1H), 4.49-4.46(m, 1H), 4.31(s, 2H), 3.94(d, J =1.6Hz, 1H), 3.78-3.68(m, 1H), 3.54-2.47(m, 1H), 2.3-2.24(m, 1H). Note: This method is also suitable for 7-deaza-7-iodoguanine The use of nucleoside GI in the synthesis of G(AP 3 ) is different in that in the first step of reaction, G-Br/Cl can be used instead of GI, and all other reaction steps and methods are the same.

以上对本发明的具体实施例进行了描述。需要理解的是,本发明并不局限于上述特定实施方式,本领域技术人员可以在权利要求的范围内做出各种变形或修改,这并不影响本发明的实质内容。Specific embodiments of the present invention have been described above. It should be understood that the present invention is not limited to the specific embodiments described above, and those skilled in the art may make various changes or modifications within the scope of the claims, which do not affect the essence of the present invention.

Claims (4)

1.一种7-去氮-2'-脱氧-7-卤素取代鸟嘌呤核苷酸的合成方法,其特征在于,所述方法包括如下步骤:1. A synthetic method for 7-deaza-2'-deoxy-7-halogen substituted guanine nucleotides, characterized in that the method comprises the steps: 步骤一、step one, 向一单口瓶中加入化合物dG-I0.4mmol,再称取CuI1mmol和Pd(PPh3)40.04mmol加入反应瓶中,抽真空,氮气保护,铝箔包裹,加入10mlDMF,搅拌溶解,注入TEA0.8mmol和三氟乙酰丙炔胺1.2mmol,50℃搅拌13小时后,反应结束,旋出溶剂,将残余物溶于100ml乙酸乙酯,依次用饱和碳酸氢钠溶液和饱和氯化钠溶液洗涤,无水硫酸钠干燥,浓缩,用体积比为1:3的乙酸乙酯-正己烷混合溶剂进行柱层析,得0.1g白色固体即dG(AP3),产率39%;Add 0.4mmol of compound dG-I to a single-necked bottle, then weigh 1mmol of CuI and 0.04mmol of Pd(PPh 3 ) 4 into the reaction bottle, vacuumize, protect with nitrogen, wrap with aluminum foil, add 10ml of DMF, stir to dissolve, and inject 0.8mmol of TEA and trifluoroacetylpropargylamine 1.2mmol, stirred at 50°C for 13 hours, the reaction was completed, the solvent was spun out, the residue was dissolved in 100ml of ethyl acetate, washed with saturated sodium bicarbonate solution and saturated sodium chloride solution successively, no Dry over sodium sulfate, concentrate, and perform column chromatography with ethyl acetate-n-hexane mixed solvent with a volume ratio of 1:3 to obtain 0.1 g of white solid, namely dG(AP 3 ), with a yield of 39%; 步骤二、Step two, 将化合物dG(AP3)真空干燥12h,在手套箱中分别称取化合物dG(AP3)0.072mmol、三正丁胺焦磷酸盐0.145mmol、2-氯-4H-1,3,2-苯并二氧磷-4-酮0.15mmol置于三个反应管中;将三正丁胺焦磷酸盐溶于0.25mL无水DMF中,再加入0.3mL新蒸的三正丁胺,常温搅拌半小时后,把反应液注入2-氯-4H-1,3,2-苯并二氧磷-4-酮的无水DMF0.25mL溶液中,常温搅拌半小时;然后将该混合液注入到dG(AP3)中,搅拌1.5h;加入1mL3%的碘的Py-H2O溶液中,保持碘液颜色15min不退色,所述Py-H2O溶液中,Py-H2O的体积比为9:1;15min后加入2mL水,2h后,加入0.75mL3MNaCl溶液、20mL无水乙醇,-20℃冷冻12h,3200rpm下离心20min;倾去上清液,沉淀抽干溶剂后,加入浓氨水,室温搅拌5小时;减压旋出溶剂,出现棕色固体,进行RP-HPLC分析,该步RP-HPLC的条件为:柱子:C18,5μm,4.6×250mm;流速:1mL/min;流动相:20mMTEAA和EtOH,0-20%EtOH35min,可见检测器波长:650nm,保留时间t=18min;进行RP-HPLC分离,该步RP-HPLC的条件为:柱子:C18,5μm,9.4×250mm;流速:4mL/min;流动相:20mMTEAA和MeOH,0-15%MeOH25min,紫外检测器波长:254nm,保留时间t=15min,NaCl/EtOH除去乙酸三乙胺盐,得12mg白色固体即dGTP(AP3),产率26%。The compound dG(AP 3 ) was vacuum-dried for 12 hours, and the compound dG(AP 3 ) 0.072mmol, tri-n-butylamine pyrophosphate 0.145mmol, 2-chloro-4H-1,3,2-benzene Put 0.15mmol of phospho-4-one in three reaction tubes; dissolve tri-n-butylamine pyrophosphate in 0.25mL of anhydrous DMF, then add 0.3mL of freshly steamed tri-n-butylamine, stir at room temperature for half After 1 hour, inject the reaction solution into 0.25mL solution of 2-chloro-4H-1,3,2-benzodioxophosphor-4-one in anhydrous DMF, stir at room temperature for half an hour; then inject the mixture into dG (AP 3 ), stirred for 1.5 h; added 1 mL of 3% iodine in Py-H 2 O solution, kept the color of iodine solution for 15 min without fading. In the Py-H 2 O solution, the volume ratio of Py-H 2 O The ratio is 9:1; after 15 minutes, add 2 mL of water, after 2 hours, add 0.75 mL of 3M NaCl solution, 20 mL of absolute ethanol, freeze at -20°C for 12 hours, centrifuge at 3200 rpm for 20 minutes; pour off the supernatant, drain the solvent from the precipitate, and then add concentrated ammonia water , stirred at room temperature for 5 hours; spin out the solvent under reduced pressure, and a brown solid appeared, and carried out RP-HPLC analysis. The conditions of this step RP-HPLC are: column: C18, 5μm, 4.6×250mm; flow rate: 1mL/min; mobile phase: 20mM TEAA and EtOH, 0-20%EtOH35min, visible detector wavelength: 650nm, retention time t=18min; perform RP-HPLC separation, the conditions of this step RP-HPLC are: column: C18, 5μm, 9.4×250mm; flow rate: 4mL/min; mobile phase: 20mM TEAA and MeOH, 0-15% MeOH for 25min, UV detector wavelength: 254nm, retention time t=15min, NaCl/EtOH to remove triethylamine acetate salt, to obtain 12mg white solid namely dGTP(AP 3 ) , yield 26%. 2.如权利要求1所述的7-去氮-2'-脱氧-7-卤素取代鸟嘌呤核苷酸的合成方法,其特征在于,所述化合物dG-I的制备具体步骤为:将下式(Ⅴ)化合物在碱性条件下去甲基得到下,即所述7-去氮-2'-脱氧-7-卤素取代鸟嘌呤核苷;2. the synthetic method of 7-deaza-2'-deoxy-7-halogen substituted guanine nucleotides as claimed in claim 1, is characterized in that, the preparation specific steps of described compound dG-1 are: the following The compound of formula (V) is demethylated under basic conditions, that is, the 7-deaza-2'-deoxy-7-halogen substituted guanosine; 其中R2为I; Wherein R 2 is 1; 所述式(Ⅴ)化合物通过在碱性条件下将式(Ⅳ)化合物去保护基制备而得:The compound of formula (V) is prepared by deprotecting the compound of formula (IV) under basic conditions: 其中,R为保护羟基或氨基的保护基; Wherein, R is a protecting group for protecting a hydroxyl group or an amino group; 所述保护基为新戊酰基或异丁酰基;The protecting group is pivaloyl or isobutyryl; 所述式(Ⅳ)化合物通过在式(Ⅲ)化合物的嘌呤碱基的7位接上卤素制备而得:The compound of the formula (IV) is prepared by connecting a halogen to the 7-position of the purine base of the compound of the formula (III): 所述式(Ⅲ)化合物通过在碱性条件下用保护基保护式(Ⅱ)化合物的两个羟基和一个氨基制备而得:The compound of formula (III) is prepared by protecting two hydroxyl groups and one amino group of the compound of formula (II) with a protecting group under basic conditions: 3.如权利要求1所述的7-去氮-7-丙炔胺-2'-去氧鸟嘌呤核苷酸的合成方法,其特征在于,步骤一中,所述dG-I化合物、三氟乙酰丙炔胺、CuI、Pd(PPh3)4和TEA的摩尔比为1:(2~3):0.072:0.025:(1.5~2)。3. the synthetic method of 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide as claimed in claim 1, is characterized in that, in step 1, described dG-I compound, three The molar ratio of fluoroacetylpropargylamine, CuI, Pd(PPh 3 ) 4 and TEA is 1:(2~3):0.072:0.025:(1.5~2). 4.如权利要求1所述的7-去氮-7-丙炔胺-2'-去氧鸟嘌呤核苷酸的合成方法,其特征在于,步骤二中,所述三正丁胺焦磷酸盐、2-氯-4H-1,3,2-苯并二氧磷-4-酮和dG(AP3)的摩尔比为2:2:1。4. the synthetic method of 7-deaza-7-propynylamine-2'-deoxyguanine nucleotide as claimed in claim 1, is characterized in that, in step 2, described tri-n-butylamine pyrophosphate The molar ratio of salt, 2-chloro-4H-1,3,2-benzodioxophosphor-4-one and dG(AP 3 ) was 2:2:1.
CN201310489397.0A 2013-10-17 2013-10-17 The synthetic method of 7-denitrification-2 '-deoxidation-7-halogen 9 substituted guanine nucleosides Active CN103601779B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310489397.0A CN103601779B (en) 2013-10-17 2013-10-17 The synthetic method of 7-denitrification-2 '-deoxidation-7-halogen 9 substituted guanine nucleosides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310489397.0A CN103601779B (en) 2013-10-17 2013-10-17 The synthetic method of 7-denitrification-2 '-deoxidation-7-halogen 9 substituted guanine nucleosides

Publications (2)

Publication Number Publication Date
CN103601779A CN103601779A (en) 2014-02-26
CN103601779B true CN103601779B (en) 2016-05-04

Family

ID=50120057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310489397.0A Active CN103601779B (en) 2013-10-17 2013-10-17 The synthetic method of 7-denitrification-2 '-deoxidation-7-halogen 9 substituted guanine nucleosides

Country Status (1)

Country Link
CN (1) CN103601779B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588838A (en) * 2013-10-30 2014-02-19 上海交通大学 Synthesis method of base modified nucleotide and application thereof
CN103819523B (en) * 2014-01-22 2016-02-10 上海交通大学 The synthetic method of 7-denitrification-7-halogen guanosine-

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320706A (en) * 2000-03-27 2001-11-07 有机合成药品工业株式会社 Method for preparing guanosine compounds and intermediates thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296645A1 (en) * 2000-10-06 2002-04-15 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding dna and rna
US7982029B2 (en) * 2005-10-31 2011-07-19 The Trustees Of Columbia University In The City Of New York Synthesis of four color 3′O-allyl, modified photocleavable fluorescent nucleotides and related methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320706A (en) * 2000-03-27 2001-11-07 有机合成药品工业株式会社 Method for preparing guanosine compounds and intermediates thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
7-Functionalized 7-Deazapurine Ribonucleosides Related to 2-Aminoadenosine, Guanosine, and Xanthosine: Glycosylation of Pyrrolo[2,3-d]pyrimidines with 1-O-Acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose;Frank Seela 等;《Journal of Organic Chemistry》;20051201;第71卷(第1期);第81-90页 *
7-Substituted 7-deaza-2’-deoxyguanosines: regioselective halogenation of pyrrolo[2,3-d]pyrimidine nucleosides;Natalya Ramzaeva 等;《Helvetica Chimica Acta》;19951231;第78卷(第5期);第1083-1090页 *

Also Published As

Publication number Publication date
CN103601779A (en) 2014-02-26

Similar Documents

Publication Publication Date Title
CN100491339C (en) A kind of synthetic technology of antineoplastic drug melphalan
CN104292117B (en) Acid-sensitive connects the synthesis of unit and the purposes in DNA sequencing thereof
TW202220976A (en) Cd73 inhibitor and application thereof in medicine
CN107235923A (en) The preparation method of the aryl quinokysalines derivative of one class 3
CN112142638A (en) Chiral binaphthyl-aza polycyclic ligand and preparation method thereof
CN103601779B (en) The synthetic method of 7-denitrification-2 '-deoxidation-7-halogen 9 substituted guanine nucleosides
CN107474091A (en) The synthesis and application of 5 aldehyde radical cytidine phosphoramidite monomers of photosensitive protective group protection and preparation method thereof and oligonucleotide
CN103601778A (en) Synthetic method of 7-denitrified-7-substituted guanosine
CN113683651A (en) A kind of preparation method of GalNAc intermediate
CN103864889B (en) Epoxy ketone compound, preparation method thereof and preparation method of kyprolis
WO2025082371A1 (en) Liver-targeting compound, oligonucleotide conjugate thereof, coupling method therefor and use thereof
CN104693258B (en) Fluorescence-labeled nucleotides based on molecular glue and its purposes in DNA sequencing
CN117946007A (en) A curcumin-amino acid methyl ester derivative and its preparation method and application
CN105732631A (en) N9 vinylpurine and synthesis method thereof, and method for synthesizing polysubstituted chiral azacyclonucleoside analogs from N9 vinylpurine
CN103232507B (en) Modified nucleoside monomer and synthetic method thereof and application
CN112920053B (en) Preparation method of chiral alpha-methyl aromatic ethylamine
CN103819523B (en) The synthetic method of 7-denitrification-7-halogen guanosine-
WO2018113277A1 (en) Method for preparing ledipasvir and intermediate for preparing ledipasvir
CN108610358B (en) 3-(Trimethylsilyl)pyrrolidine-2-carboxylic acid, its intermediate and its preparation and application
CN109608434B (en) Preparation method of lenalidomide
CN108586486B (en) A kind of preparation method of aryl-substituted thienopyrimidine compounds
CN117567536A (en) Application of fluorescently labeled nucleotides in DNA synthesis sequencing and single-molecule sequencing
CN105037374B (en) Preparation method of N-butyl-9H-pyrido[4,5-b]indole-2-carboxamide
CN120535564B (en) Preparation method of SAR LINKER-containing polypeptide
KR101354692B1 (en) Oligomer and the synthesis of the oligomer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant